Literature DB >> 25618774

Molecular drivers of cellular metabolic reprogramming in melanoma.

Cecilie Abildgaard1, Per Guldberg2.   

Abstract

The development of metastatic melanoma is accompanied by distinct changes in cellular metabolism, most notably a change in strategy for energy production from mitochondrial oxidative phosphorylation to cytoplasmic aerobic glycolysis. This bioenergetic switch occurs at the expense of less-efficient utilization of glucose, but is required for melanoma cells to meet their bioenergetic and biosynthetic demands. Recent work has implicated well-established melanoma drivers such as BRAF, PTEN, MITF, and ARF in the regulation of cellular energy metabolism. The metabolic changes in melanoma cells offer new opportunities for therapeutic intervention. However, inter- and intratumor bioenergetic heterogeneity caused by variation in genetic driver profiles and mitochondrial performance may impact on the effectiveness of treatment.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRAF; melanoma; metabolism; mitochondria; oncogene

Mesh:

Substances:

Year:  2015        PMID: 25618774     DOI: 10.1016/j.molmed.2014.12.007

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  54 in total

1.  A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells.

Authors:  Jelena Grahovac; Marijana Pavlović; Marija Ostojić
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Authors:  Grant M Fischer; Y N Vashisht Gopal; Jennifer L McQuade; Weiyi Peng; Ralph J DeBerardinis; Michael A Davies
Journal:  Pigment Cell Melanoma Res       Date:  2017-11-02       Impact factor: 4.693

3.  Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization.

Authors:  Amandine Verlande; Michaela Krafčíková; David Potěšil; Lukáš Trantírek; Zbyněk Zdráhal; Moustafa Elkalaf; Jan Trnka; Karel Souček; Nora Rauch; Jens Rauch; Walter Kolch; Stjepan Uldrijan
Journal:  EMBO Rep       Date:  2017-12-20       Impact factor: 8.807

Review 4.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

5.  Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition.

Authors:  Andrew P Trotta; Jesse D Gelles; Madhavika N Serasinghe; Patrick Loi; Jack L Arbiser; Jerry E Chipuk
Journal:  J Biol Chem       Date:  2017-05-25       Impact factor: 5.157

6.  Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.

Authors:  Ming-Zhao Gao; Hong-Bin Wang; Xiang-Ling Chen; Wen-Ting Cao; Li Fu; Yun Li; Hai-Tian Quan; Cheng-Ying Xie; Li-Guang Lou
Journal:  Acta Pharmacol Sin       Date:  2018-05-18       Impact factor: 6.150

7.  Melanoma therapeutics: a literature review.

Authors:  Pavan Kumar Dhanyamraju; Trupti N Patel
Journal:  J Biomed Res       Date:  2022-02-28

8.  Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations.

Authors:  Serena Stamatakos; Giovanni Luca Beretta; Elisabetta Vergani; Matteo Dugo; Cristina Corno; Elisabetta Corna; Stella Tinelli; Simona Frigerio; Emilio Ciusani; Monica Rodolfo; Paola Perego; Laura Gatti
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

Review 9.  Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications.

Authors:  Alice Indini; Francesco Grossi; Mario Mandalà; Daniela Taverna; Valentina Audrito
Journal:  Biomedicines       Date:  2021-05-26

10.  Bergamottin Induces DNA Damage and Inhibits Malignant Progression in Melanoma by Modulating miR-145/Cyclin D1 Axis.

Authors:  Zhongfang Zhao; Nong Liao
Journal:  Onco Targets Ther       Date:  2021-06-17       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.